A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer

Oncology

Volumn 68, Issue 4-6, 2005, Pages 333-340

  Eun, Kyung Cho ^a   Woon, Ki Lee ^a   Im, Seok Ah ^b   Soon, Nam Lee ^c   Se, Hoon Park ^a   Bang, Soo Mee ^a   Dong, Kyun Park ^a   Yeon, Ho Park ^a   Dong, Bok Shin ^a   Jae, Hoon Lee ^a  

^a Gachon University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

Author keywords

Capecitabine; Cisplatin; Epirubicin; Gastric neoplasms

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SEPSIS; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 23844513760     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086972     Document Type: Article

References (29)

1. Pisani P, Parkin DM, Bray F, Ferlay J: Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Bae JM, Won YJ, Jung KW, Park JG: Annual report of the Korea Central Cancer Registry program 2000: Based on registered data from 131 hospitals. Cancer Res Treat 2002;34:77-83.
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrignes MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
5. Kyoto Research Group for Chemotherapy of Gastric Cancer: A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cis-platin (FP) versus 5-fluorouracil, cisplatin, and 4′-epirubicin (FPEPIR). Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC). Anticancer Res 1992;12:1983-1988.
6. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609-616.
7. Bamias A, Hill ME, Cunningham D, Norman AR, Ahmed FY, Webb A, Watson M, Hill AS, Nicolson MC, O'Brien ME, Evans TC, Nicolson V: Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: Response, toxicity, quality of life, and survival. Cancer 1996;77:1978-1985.
8. Cho EK, Lee WK, Lim DY, Bang S, Park DK, Park Y, Kwon OS, Choi DJ, Shin DB, Lee JH, Lee TH: Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma. J Korean Med Sci 2002;17:348-352.
9. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underbill C, Wardley A, Meehan M: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
10. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999;80:269-272.
11. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
12. Kikuyama S, Inada T, Shimizu K, Miyakita M: Thymidine phosphorylase expression in gastric cancer in association with proliferative activity and angiogenesis. Anticancer Res 2000;20:2081-2086.
13. Ogawa K, Konno S, Takebayashi Y, Miura K, Katsube T, Kajiwara T, Aiba M, Aikou T, Akiyama S: Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma. Anticancer Res 1999;19:4363-4367.
14. Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T; Clinical Study Group of Capecitabine: A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003;64:232-236.
15. Ishitsuka H: Capecitabine: Preclinical pharmacology studies. Invest New Drugs 2000;18:343-354.
16. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002;13:1893-1898.
17. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij J: Phase I and pharmacodynamic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998;16:2977-2985.
18. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Scholmerich J, Burger HU, Verweij J: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study. J Clin Oncol 2000;18:1337-1345.
19. Evans TRJ, Pentheroudakis G, Pail J, McInnes A, Blackie R, Raby N, Morrison R, Fullarton GM, Soukop M, McDonald AC: A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 2002;13:1469-1478.
20. Simon R, Wittes RE, Ellemberg SS: Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381.
21. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-432.
22. Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, Ritch P, Chitambar C, Vukelich M: Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988;11:461-464.
23. Tsujinaka T, Kido Y, Shiozaki H, Iijima S, Homma T, Sakaue M, Mori T: Schedule-dependent inhibition of thymidylate synthase by 5-fluorouracil in gastric cancer. Cancer 1992;70:2761-2765.
24. Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, Akazawa S, Betsuyaku T, Ohkubo S, Takahashi H, et al.: A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 1993;72:658-662.
25. Jeen YT, Yoon SY, Shin SW, Kim BS, Mok YJ, Kim CS, Hyun JH, Kim JS, Kim YH: Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer 2001;91:2288-2293.
26. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastrix cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-59.
27. Sumpter KA, Harper-Wynne C, Cunningham D, Oates J, Tebbutt N, Iveson T, Nicholson M, Hickish T, Hill M, Norman A: Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced esophagogastric cancer: Confirmation of dose escalation. Proc Am Soc Clin Oncol 2003;22:257 (abst 1031).
28. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-1720.
29. Koizumi W, Kurihara M, Nakano S, Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-197.